Alankar Garude

“First question, Vinita, are you evaluating the possibility of a partner for a Pixabend?”

“Hi, thank you for the opportunity and congrats to the team on pretty good performance as well as the increase in the guidance. So first question on domestic growth, you have spoken about Juventus performance improving sequentially.”

“Sir, can you take us through the technology platforms that you have been working on over the past few years? You've spoken about flow chemistry in the past and how some of these initiatives have been helping improve the quality of the portfolio, as you mentioned, and hence that repercussion on EBITDA margins.”

“Within peptides, how important do you think will be purification as your programs move from clinical to commercial over the next two years? And this is particularly for the longer peptides.”

“I have another question on OTC, more or less in continuation with the previous participant. See, growth has been sluggish for the company for almost four years now in OTC.”